Abstract:Abstract PKB/AKT kinase is the core component of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway which is one of the most frequently hyperactivated signaling pathways in human cancers. We designed and synthesized a series of 2-pyrimidyl-5-amidothiazole coumpounds based on the ATP binding site of AKT kinase, and the most potent compound DC120 was identified to inhibit AKT kinase activity in vitro with EC50 of 153nM by a FRET-based Z'-Lyte assay. Then the growth inhibition of DC120 on human CNE2 and MDA-MB-453 cell lines was tested in vitro. The results showed DC120 could obviously inhibit the proliferation of these cancer cell lines via induction of apoptosis, with the evidence of increasing sub-G1 cells, characteristic morphologic changes of apoptosis in the nucleus, and cleaved caspase-3 and PARP. Further study showed that MDA-MB-453 cells transfected with constitutively activated AKT1 were more sensitive to DC120, while CNE2 cells with knock-down of AKT1 expression by shRNA were more resistant to DC120. More importantly, DC120 attenuated the phosphorylation levels of FKHR, FKHRL1, GSK-3 and mTOR in a dose-dependent and time-dependent fashion, and led to an increase in the nuclear accumulation of exogenous FKHR in cancer cells. Additionally, the in vivo experiments showed DC120 at 20 mg/kg/qd remarkably inhibited the CNE2 xenograft tumor growth with the T/C value of 36.1%, accompanied by increasing TUNEL-positve cells in tumor sample. These data provide validation for the development of DC120 to treat cancers displaying elevated levels of AKT. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C86.

Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers

Remodeling Tumor-Associated Macrophage for Anti-Cancer Effects by Rational Design of Irreversible Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2

Targeted Inhibition of ACK1 Can Inhibit the Proliferation of Hepatocellular Carcinoma Cells Through the PTEN/AKT/mTOR Pathway.

Activated Cdc42-Associated Kinase is Up-Regulated in Non-Small-cell Lung Cancer and Necessary for FGFR-mediated AKT Activation.

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--opportunities, Challenges, and Limitations.

ACK1 is dispensable for development, skin tumor formation, and breast cancer cell proliferation

Targeting cancer with small molecule kinase inhibitors

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

Small Molecule in the Treatment of Cancer

Small molecule activation of the tumor suppressor kinase LKB1

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)

Therapeutic potential of ASK1 activators in cancer treatment: Current insights and future directions

Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases

Receptor Tyrosine Kinases: Biological Functions and Anticancer Targeted Therapy

Design, Synthesis, and Evaluation of ( R )-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3- d ]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor

MNK: A Novel Promising Target for Cancer Immunotherapy

Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

Abstract C86: DC120, a Novel and Potent Inhibitor of AKT Kinase, Induces Tumor Cells Apoptosis and Suppresses Tumor Growth.

Selective TBK1/IKKi dual inhibitors with anticancer potency